Skip to main content

Advertisement

SpringerLink
Log in

A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Women starting first-line chemotherapy for advanced breast cancer have differing baseline characteristics and survival times. We sought to develop and validate a pragmatic prognostic nomogram to predict overall survival (OS) by using available clinical and laboratory data. The prognostic model was developed in a training cohort (n = 693) from two first-line chemotherapy trials (ANZ8101 and ANZ8614) and validated in two other trials (ANZ0001 and ANZ9311) with 324 and 233 patients, respectively. The proportional-hazards model was constructed from pretreatment demographic and disease characteristics. Patients were classified into good (score <88), medium (88–157), and poor (>157) prognostic groups. A nomogram was constructed (n = 1250) from the combined datasets of all four trials, based on the predictors identified in the training cohort. The nomogram predicted OS with a concordance index of 0.65 (95%CI, 0.62–0.67). Factors in the nomogram were age, performance status, estrogen receptor status, number of involved organs (lung, liver and brain), hemoglobin concentration, neutrophil count, and serum alkaline phosphatase. The median survival for good, medium, and poor prognosis was 15.4 months (95%CI, 12.7–19.1), 10.2 months (95%CI, 9.0–11.6), and 6.1 months (95%CI, 4.4–6.7), respectively. The actual and model-predicted probabilities of 18-month survival agreed well, after recalibration for the new baseline survival functions for each validation cohort. A nomogram combining seven readily available baseline characteristics enabled stratification of advanced breast cancer patients into three groups with significantly different survival times. This nomogram could be useful for individualising treatment and for stratifying patients in future randomized trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn H-J (2009) Thresholds for therapies: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329

    Article  PubMed  CAS  Google Scholar 

  2. Greene F, Page D, Fleming I et al (2002) AJCC cancer staging manual American joint committee on cancer. Chicago, IL

    Google Scholar 

  3. Galea M, Blamey R, Elston C, Ellis I (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22:207–219

    Article  PubMed  CAS  Google Scholar 

  4. Ravdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980–991

    PubMed  CAS  Google Scholar 

  5. Largillier R, Ferrero J-M, Doyen J et al (2008) Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 19:2012–2019

    Article  PubMed  CAS  Google Scholar 

  6. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period. Cancer 104:1742–1750

    Article  PubMed  Google Scholar 

  7. Hortobagyi G, Smith T, Legha S et al (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1:776–786

    PubMed  CAS  Google Scholar 

  8. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003) Survival of patients with metastatic breast carcinoma. Cancer 97:545–553

    Article  PubMed  Google Scholar 

  9. Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P (2001) Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol 12:81–87

    Article  PubMed  CAS  Google Scholar 

  10. Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16:2401–2408

    PubMed  CAS  Google Scholar 

  11. Swenerton KD, Legha SS, Smith T et al (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552–1562

    PubMed  CAS  Google Scholar 

  12. Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592

    Article  PubMed  Google Scholar 

  13. Stockler MR, Tattersall MHN, Boyer MJ, Clarke SJ, Beale PJ, Simes RJ (2005) Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 94:208–212

    Article  Google Scholar 

  14. Viganò A, Dorgan M, Bruera E, Suarez-Almazor ME (1999) The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Cancer 86:170–176

    Article  PubMed  Google Scholar 

  15. Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME (2000) Clinical survival predictors in patients with advanced cancer. Arch Intern Med 160:861–868

    Article  PubMed  CAS  Google Scholar 

  16. Glare P, Virik K, Jones M et al (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327:195

    Article  PubMed  Google Scholar 

  17. Coates A, Gebski V, Bishop J et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490–1495

    Article  PubMed  CAS  Google Scholar 

  18. Simes R, Gebski V, Coates A et al (1994) Quality of life with single agent mitozantrone or combination chemotherapy for advanced breast cancer, a randomised trial. Proc Am Soc Clin Oncol 13:73

    Google Scholar 

  19. Stockler M, Sourjina T, Harvey V et al (2007) A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Res Treat 100:S278

    Google Scholar 

  20. Ackland S, Gebski V, Wilson A et al (2000) High dose epirubicin & cyclophosphamide (HDEC) with filgrastim versus standard dose (SDEC) in advanced breast cancer—a quality of life study by the anz breast cancer trials group. Proc Am Soc Clin Oncol 19 (abstr 288)

  21. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  22. Cox DR (1972) Regression models and life-tables. J Royal Stat Soc 34:187–220

    Google Scholar 

  23. Harrell F Jr, Lee K, Mark D (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387

    Article  PubMed  Google Scholar 

  24. Harrell F Jr (2001) Regression modeling strategies: with applications to linear models, logistic regression and survival analysis. Springer, New York

    Google Scholar 

  25. Lee CK, Lord SJ, Stockler MR, Coates AS, Gebski V, Simes RJ (2010) Historical cross-trial comparisons for competing treatments in advanced breast cancer—an empirical analysis of bias. Eur J Cancer 46:541–548

    Article  PubMed  CAS  Google Scholar 

  26. Kattan MW, Scardino PT (2002) Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer 1:90–96

    PubMed  Google Scholar 

  27. Henderson R, Keiding N (2005) Individual survival time prediction using statistical models. J Med Ethics 31:703–706

    Article  PubMed  CAS  Google Scholar 

  28. Dunkler D, Michiels S, Schemper M (2007) Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 43:745–751

    Article  PubMed  CAS  Google Scholar 

  29. Kattan M (2002) Statistical prediction models, artificial neural networks, and the sophism “I Am a Patient, Not a Statistic”. J Clin Oncol 20:885–887

    Article  PubMed  Google Scholar 

  30. Ghersi D, Wilcken N, Simes RJ (2005) A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93:293–301

    Article  PubMed  CAS  Google Scholar 

  31. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  32. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  PubMed  CAS  Google Scholar 

  33. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  PubMed  CAS  Google Scholar 

  34. Saad ED, Katz A, Buyse M (2010) Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 28:1958–1962

    Article  PubMed  Google Scholar 

  35. Lee CK, Stockler MR, Coates AS, Gebski V, Lord SJ, Simes RJ (2010) Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer 102(9):1341–1347

    Article  PubMed  CAS  Google Scholar 

  36. Seshadri R, Firgaira F, Horsfall D, McCaul K, Setlur V, Kitchen P (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian breast cancer study group. J Clin Oncol 11:1936–1942

    PubMed  CAS  Google Scholar 

  37. Slamon D, Godolphin W, Jones L et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712

    Article  PubMed  CAS  Google Scholar 

  38. Bartsch R, Rottenfusser A, Wenzel C et al (2007) Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 85:311–317

    Article  PubMed  CAS  Google Scholar 

  39. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  40. Toikkanen S, Helin H, Isola J, Joensuu H (1992) Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10:1044–1048

    PubMed  CAS  Google Scholar 

  41. Bewick M, Conlon M, Gerard S et al (2001) HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. Bone Marrow Trans 27:847–853

    Article  CAS  Google Scholar 

  42. Kiely BE, Soon YY, Tattersall MHN, Stockler MR (2011) How Long Have I Got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 29:456–463

    Article  PubMed  Google Scholar 

  43. Schapira L (2011) Simple rules can improve prognostic accuracy. J Clin Oncol 29:347–349

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Ms Rhana Pike for the editorial support. This study was supported by National Breast Cancer Foundation Doctoral Research Scholarship for Dr CK Lee.

Author information

Authors and Affiliations

  1. NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown,, NSW 1450, Australia

    C. K. Lee, M. Hudson, M. Stockler, A. S. Coates, S. Ackland, V. Gebski, S. Lord, M. Friedlander, F. Boyle & R. J. Simes

Authors
  1. C. K. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Hudson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Stockler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. S. Coates
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Ackland
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Gebski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Lord
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Friedlander
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. Boyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. J. Simes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. K. Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, C.K., Hudson, M., Stockler, M. et al. A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Res Treat 129, 467–476 (2011). https://doi.org/10.1007/s10549-011-1471-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1471-9

Keywords

Search

Navigation